文献速递消化道肿瘤与早癌消化内镜炎症性肠病

2003至2012年瑞典结肠镜检查后结直肠癌:生存、肿瘤特征与危险因素

Postcolonoscopy Colorectal Cancer in Sweden From 2003 to 2012: Survival, Tumor Characteristics, and Risk Factors.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-06-15

基于瑞典2003至2012年458937例结肠镜检查的 population-based 队列研究,计算结肠镜检查后3年内结直肠癌(PCCRC)发生率并分析其危险因素、生存与肿瘤特征。PCCRC比例从2003年9.4%降至2012年6.1%,既往结直肠癌、溃疡性结肠炎、克罗恩病和既往息肉切除是最大危险因素;PCCRC患者生存短于指数结肠镜检出者,男性多变量HR 2.75、女性HR 2.00。

要点

  • PCCRC比例从2003年9.4%降至2012年6.1%。
  • 既往结直肠癌、溃疡性结肠炎、克罗恩病和既往息肉切除是PCCRC最大危险因素。
  • PCCRC患者生存短于指数结肠镜检出者,男性多变量HR 2.75、女性HR 2.00。

核心结论

  • 在瑞典结肠镜分析中,PCCRC比例从2003年9.4%降至2012年6.1%。
  • 需要监测的疾病(如既往结直肠肿瘤和炎症性肠病)是PCCRC最大危险因素。
  • PCCRC患者生存短于初次结肠镜检出结直肠癌者,尤其是女性和左侧肿瘤患者。

研究设计与样本

  • 基于瑞典数据库的 population-based 队列研究,纳入2003至2012年458937例结肠镜检查,女性占54.0%。
  • 按世界内镜组织指南计算结肠镜检查后3年内结直肠癌发生率,采用泊松回归评估危险因素。
  • 采用Cox回归模型和Kaplan-Meier分析按性别分层评估条件生存,采用逻辑回归评估肿瘤特征。

主要发现

  • 结肠镜检查后36个月内19184例诊断为结直肠癌,其中1384例为PCCRC(7.2%)。
  • PCCRC比例从2003年9.4%降至2012年6.1%。
  • PCCRC最大危险因素为既往结直肠癌诊断(RR 3.31;95%CI 2.71-4.04)、溃疡性结肠炎(RR 5.44;95%CI 4.75-6.23)、克罗恩病(RR 3.81;95%CI 2.98-4.87)和既往息肉切除(RR 2.32;95%CI 1.97-2.72)。
  • PCCRC多变量风险比男性为2.75(95%CI 2.21-3.42),女性为2.00(95%CI 1.59-2.52)。
  • 结肠镜检查后结直肠肿瘤低分化几率高于指数结肠镜检出肿瘤(OR 1.27;95%CI 1.09-1.49)。

关键数值与推荐

  • PCCRC定义为结肠镜检查后3年内结直肠癌,按世界内镜组织指南计算。
  • PCCRC比例从2003年9.4%降至2012年6.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The rate of postcolonoscopy colorectal cancer (PCCRC) is a measure of colonoscopy quality, but there are conflicting results from studies of survival times of patients with PCCRC. We assessed survival times of patients with PCCRC and characterized the microscopic and macroscopic features of postcolonoscopy colorectal tumors. METHODS: We performed a population-based cohort study using data from a database in Sweden, on 458,937 colonoscopies (54.0% women) performed from 2003 through 2012. Rates of colorectal cancer within 3 years of a colonoscopy were calculated based on the World Endoscopy Organization guidelines. Risk factors were evaluated using Poisson regression analysis. We used Cox regression models and Kaplan-Meier analyses, stratified by sex, to assess conditional survival. Logistic regression models were used to evaluate features of postcolonoscopy colorectal tumors, including stage location (right, left, or rectum) differentiation grade (high or low), synchronous tumors, perineural growth, resection margins, and mucinous and vessel characteristics. RESULTS: Within 36 months after a colonoscopy, there were 19,184 individuals who had received a diagnosis of CRC; 1384 of these were PCCRCs (7.2%). The proportion of individuals with PCCRC decreased from 9.4% in 2003 to 6.1% in 2012. The largest risk factors for PCCRC were a prior diagnosis of CRC (relative risk [RR], 3.31; 95% CI, 2.71-4.04), ulcerative colitis (RR, 5.44; 95% CI, 4.75-6.23), Crohn's disease (RR, 3.81; 95% CI, 2.98-4.87), and prior polypectomy (RR, 2.32; 95% CI, 1.97-2.72). Individuals with PCCRCs had shorter survival times than individuals with CRCs detected during the index colonoscopy. Multivariate hazard ratios for PCCRC were 2.75 for men (95% CI, 2.21-3.42) and 2.00 for women (95% CI, 1.59-2.52), respectively. Individuals with left-side PCCRC had shorter survival times than patients with CRC detected during the index colonoscopy. Postcolonoscopy colorectal tumors had increased odds of low differentiation grade (odds ratio, 1.27; 95% CI, 1.09-1.49) compared with colorectal tumors detected during the index colonoscopy. CONCLUSIONS: In an analysis of colonoscopies in Sweden, the rate of PCCRCs decreased from 9.4% in 2003 to 6.1% in 2012. Diseases that require surveillance (such as prior colorectal neoplasms and inflammatory bowel diseases) are the largest risk factors for PCCRC. Patients with PCCRC have shorter survival times than patients with CRC detected during their initial colonoscopy-especially women and patients with left-side tumors.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Forsberg A, Widman L, Bottai M, et al. Postcolonoscopy Colorectal Cancer in Sweden From 2003 to 2012: Survival, Tumor Characteristics, and Risk Factors. Clin Gastroenterol Hepatol. 2020. PMID: 32553903. doi:10.1016/j.cgh.2020.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。